Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types.
Bristol-Myers Squibb is attractively valued, offers a 5%+ dividend yield, and benefits from a strong oncology pipeline after its BioNTech deal. The $11B BioNTech partnership gives BMY access to BNT327, targeting large cancer markets, with a deal structure that limits BMY's downside risk. BMY's established cash flows, low payout ratio, and current low valuation make it a safer, income-generating pick versus higher-risk, growth-oriented BioNTech.
Bristol Myers Squibb (BMY) closed the most recent trading day at $48.79, moving +1.06% from the previous trading session.
![]() BMY In 3 weeks Estimated | Quarterly | $0.62 Per Share |
![]() BMY 2 months ago Paid | Quarterly | $0.62 Per Share |
![]() BMY 5 months ago Paid | Quarterly | $0.62 Per Share |
![]() BMY 8 months ago Paid | Quarterly | $0.6 Per Share |
![]() BMY 11 months ago Paid | Quarterly | $0.6 Per Share |
![]() BMY 4 Apr 2024 Paid | Quarterly | $0.6 Per Share |
31 Jul 2025 (52 Days) Date | | 1.71 Cons. EPS | - EPS |
25 Apr 2025 Date | | 1.53 Cons. EPS | - EPS |
6 Feb 2025 Date | | 1.47 Cons. EPS | 1.67 EPS |
31 Oct 2024 Date | | 1.49 Cons. EPS | 1.8 EPS |
26 Jul 2024 Date | | 1.63 Cons. EPS | 2.07 EPS |
![]() BMY In 3 weeks Estimated | Quarterly | $0.62 Per Share |
![]() BMY 2 months ago Paid | Quarterly | $0.62 Per Share |
![]() BMY 5 months ago Paid | Quarterly | $0.62 Per Share |
![]() BMY 8 months ago Paid | Quarterly | $0.6 Per Share |
![]() BMY 11 months ago Paid | Quarterly | $0.6 Per Share |
![]() BMY 4 Apr 2024 Paid | Quarterly | $0.6 Per Share |
31 Jul 2025 (52 Days) Date | | 1.71 Cons. EPS | - EPS |
25 Apr 2025 Date | | 1.53 Cons. EPS | - EPS |
6 Feb 2025 Date | | 1.47 Cons. EPS | 1.67 EPS |
31 Oct 2024 Date | | 1.49 Cons. EPS | 1.8 EPS |
26 Jul 2024 Date | | 1.63 Cons. EPS | 2.07 EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Dr. Christopher S. Boerner Ph.D. CEO | XSTU Exchange | US1101221083 ISIN |
US Country | 34,100 Employees | 4 Apr 2025 Last Dividend | 7 Aug 2001 Last Split | - IPO Date |
Bristol-Myers Squibb Company is an eminent global biopharmaceutical firm engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative biopharmaceutical products. With a spectrum of treatments covering hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases, the company has established a significant footprint in the healthcare sector. Initially founded as Bristol-Myers Company in 1887, it has evolved over the decades to become a leader in the biopharmaceutical industry, headquartered in Princeton, New Jersey. The company's operational reach spans globally, selling products through a diversified channel mix including wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.